Outcomes among Thai children with risk conditions hospitalized for pneumococcal disease (invasive or non-bacteraemic pneumonia): A multi-centre, observational study
Issued Date
2023-09-01
Resource Type
eISSN
27727076
Scopus ID
2-s2.0-85163032478
Journal Title
IJID Regions
Volume
8
Start Page
49
End Page
57
Rights Holder(s)
SCOPUS
Bibliographic Citation
IJID Regions Vol.8 (2023) , 49-57
Suggested Citation
Phongsamart W., Allen K.E., Vandepitte W.P., Techasaensiri C., Kosalaraksa P., Laoprasopwattana K., Khantee P., Udompornwattana S., Suwanpakdee D., Sudjaritruk T., Puthanakit T., Anugulruengkitt S., Southern J., Fletcher M.A., Dunne E.M., Thamaree R., Morales G., Chokephaibulkit K., Chotpitayasunondh T. Outcomes among Thai children with risk conditions hospitalized for pneumococcal disease (invasive or non-bacteraemic pneumonia): A multi-centre, observational study. IJID Regions Vol.8 (2023) , 49-57. 57. doi:10.1016/j.ijregi.2023.06.001 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/87788
Title
Outcomes among Thai children with risk conditions hospitalized for pneumococcal disease (invasive or non-bacteraemic pneumonia): A multi-centre, observational study
Author's Affiliation
Ramathibodi Hospital
Siriraj Hospital
Faculty of Medicine, Chiang Mai University
Faculty of Medicine, Khon Kaen University
Faculty of Medicine, Prince of Songkia University
Buddhachinaraj Hospital
Queen Sirikit National Institute of Child Health
Pfizer Inc.
Phramongkutklao College of Medicine
Faculty of Medicine, Chulalongkorn University
Pfizer Biopharma Group
Pfizer Biopharma Group
Siriraj Hospital
Faculty of Medicine, Chiang Mai University
Faculty of Medicine, Khon Kaen University
Faculty of Medicine, Prince of Songkia University
Buddhachinaraj Hospital
Queen Sirikit National Institute of Child Health
Pfizer Inc.
Phramongkutklao College of Medicine
Faculty of Medicine, Chulalongkorn University
Pfizer Biopharma Group
Pfizer Biopharma Group
Other Contributor(s)
Abstract
Objective: To describe the risk condition status and clinical outcomes among Thai children hospitalized with pneumococcal disease. Methods: In this retrospective analysis, children with invasive pneumococcal disease (IPD) or x-ray-confirmed non-bacteraemic pneumococcal pneumonia (NBPP) were identified from nine hospitals in Thailand between 2010 and 2019. Data on risk factors and outcomes were extracted from medical records. Results: In total, 413 cases were identified: 319 IPD and 94 NBPP. Overall, 133 (32.2%) patients were admitted to intensive care units and 11/406 (2.7%) died. Twenty-seven percent of IPD cases had at-risk conditions and 15% had high-risk conditions. Most IPD cases (32.9%) occurred in children aged 2–4 years, and most NBPP cases (28.7%) occurred in infants aged 0–11 months. Of 51 Streptococcus pneumoniae isolates collected, 41 (80%) were pneumococcal 13-valent conjugate vaccine serotypes. Only 5.1% of children had received a pneumococcal vaccine. Conclusions: Most children with IPD and NBPP did not have high-risk or at-risk conditions, while 42% had at-risk or high-risk conditions for pneumococcal disease. Very few children in the cohort had received any type of pneumococcal vaccine. Increasing the availability of pneumococcal conjugate vaccines should be considered to reduce the burden of pneumococcal disease among children in Thailand.